Department of Pharmacy
Permanent URI for this collectionhttp://localhost:4000/handle/123456789/1931
Browse
2 results
Search Results
Item Meander-gated dual cap gan hemt-based portable noninvasive covid-19 detection platform(AIP, 2024) Taliyan, RajeevIn this Letter, an epitaxial and device design has been proposed for the noninvasive detection of COVID-19 using a portable hand-held system. A ∼1.5-fold enhancement in sensitivity was observed for the meander-gated biosensor as compared to the conventional design. The sensitivity was further enhanced by ∼1.70 times when a dual cap layer was used instead of a conventional epitaxial design. A peak sensitivity of 252.70 μA/pg/ml with good linearity was observed for IL-6 detection in hyposmia. Thus, the importance of biosensor epitaxial and device design has been demonstrated. Saliva-based noninvasive detection of IL-6 in COVID-19 offers a sensitivity of 22.96 μA/pg/ml. The biosensing platform has a shelf-life of around 4 weeks with a minute change of ∼1.26% in sensitivity, fast detection (<10 s), limit of detection of 0.24 fg/ml, and a linear dynamic range of 0.1–80.0 pg/ml. The proposed biosensing platform has the potential for early detection, prognosis, and management of COVID-19 in point-of-care application areas.Item Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations(Elsevier, 2021-10) Taliyan, RajeevThe severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most recent coronaviruses, which has infected humans, and caused the disease COVID-19. The World Health Organization has declared COVID-19 as a pandemic in March 2020. The SARS-CoV-2 enters human hosts majorly via the respiratory tract, affecting the lungs first. In few critical cases, the infection progresses to failure of the respiratory system known as acute respiratory distress syndrome acute respiratory distress syndrome may be further associated with multi-organ failure and vasoplegic shock. Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue (MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined.